Skip to main content

Manuel Comabella Lopez

Dr. Manuel Comabella earned his medical degree at the University of Barcelona, completed his neurology residency at the Neurology Department of the Hospital Universitari Vall d’Hebron (HUVH), and earned his PhD at the Universitat Autònoma de Barcelona. Since 2004, Dr. Manuel Comabella is the Head of the Clinical Neuroimmunology laboratory at the Fundació Institut de Recerca del HUVH. Since June 2008 he works as a clinical neurologist at the Department of Neurology / Neuroimmunology of the MS Centre of Catalonia (Cemcat), HUVH, Barcelona.

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Responsable Laboratori
Multiple Sclerosis Centre of Catalonia

Manuel Comabella Lopez

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Responsable Laboratori
Multiple Sclerosis Centre of Catalonia

Dr. Manuel Comabella earned his medical degree at the University of Barcelona, completed his neurology residency at the Neurology Department of the Hospital Universitari Vall d’Hebron (HUVH), and earned his PhD at the Universitat Autònoma de Barcelona. Since 2004, Dr. Manuel Comabella is the Head of the Clinical Neuroimmunology laboratory at the Fundació Institut de Recerca del HUVH. Since June 2008 he works as a clinical neurologist at the Department of Neurology / Neuroimmunology of the MS Centre of Catalonia (Cemcat), HUVH, Barcelona.

From 1996 to 1998, Dr. Manuel Comabella was a Research Fellow in Neuroimmunology at the Center for Neurologic Diseases, Brigham and Women´s Hospital, in Boston. In 2010 was awarded with the Ayudas Merck Serono in the multiple sclerosis research area. In 2011 was awarded by the Spanish Society of Neurology (SEN) with the Biogen Idec Prize to the best publication on demyelinating disorders. In 2013 was awarded by the SEN with the Novartis Prize to the best oral communication and the best publication on demyelinating disorders. In 2014 received the Neurological Disorders Award, scientific modality, granted by the SEN. In 2016 was awarded with the Ayudas Merck Serono in the multiple sclerosis research area. From 2018 to 2020, Dr. Manuel Comabella was a collaborator of the Biomedicine area at the Division of Coordination, Evaluation and Scientific and Technical Follow-up of the State Research Agency, Ministry of Science, Innovation and Universities.

Dr. Manuel Comabella is member of the Editorial Board of Journal of Neuroimmunology and Multiple Sclerosis Journal, member of the Board of the ESNI (European School of Neuroimmunology), and member of the Strategic Group of the IMSGC (International Multiple Sclerosis Genetics Consortium). He is coauthor of 297 documents indexed in MedLine (Scopus: 12916 total citations, with h-index of 54). Dr. Manuel Comabella's research interest lies in the identification of biomarkers related with different aspects of multiple sclerosis and the development of new therapeutic strategies for the disease.

Projects

Búsqueda de marcadores de bioactividad del interferón-beta alternativos a la proteína MXA

IP: Manuel Comabella Lopez
Collaborators: Sunny Malhotra Sareen, Xavier Montalban Gairín
Funding agency: Fundación Merck Salud
Funding: 20000
Reference: MERCK-2009-05
Duration: 01/04/2010 - 31/03/2011

Validación de marcadores biológicos asociados con la conversión a esclerosis múltiple en pacientes con sínddromes clínicos aislados

IP: Manuel Comabella Lopez
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 54000
Reference: FI09/00705
Duration: 07/09/2009 - 06/09/2013

Validación de marcadores biológicos asociados con la conversión a esclerosis múltiple en pacientes que presentan síndromes clínicos aislados

IP: Manuel Comabella Lopez
Collaborators: Mar Tintore Subirana
Funding agency: Instituto de Salud Carlos III
Funding: 134915
Reference: PI09/00788
Duration: 01/01/2010 - 30/06/2013

Búsqueda de nuevos tratamientos para la esclerosis múltiple mediante screening masivo de librerías de fármacos basado en perfiles de expresión génica usando mapas de conectividad

IP: Manuel Comabella Lopez
Collaborators: Jordi Rio Izquierdo, Xavier Montalban Gairín
Funding agency: Fundación Invest. Médica Mutua Madrileña
Funding: 73250
Reference: FMMA/04/2008
Duration: 04/09/2008 - 04/09/2011

Related news

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.

The research findings propose to modify the McDonald 2017 criteria, only in those in whom diagnosis using the current criteria is not possible.

Related professionals

Bruno García del Blanco

Bruno García del Blanco

Main researcher
Cardiovascular Diseases
Read more
Jordi Pradell Teigell

Jordi Pradell Teigell

General Surgery
Read more
Mercè Beltran Vilagrasa

Mercè Beltran Vilagrasa

Main researcher
Read more
Marc Ribó Jacobi

Marc Ribó Jacobi

Main researcher
Stroke research
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.